Effects of Exemestane and COX-2 inhibition on oestrogen receptor positive ductal carcinoma in situ.

Trial Profile

Effects of Exemestane and COX-2 inhibition on oestrogen receptor positive ductal carcinoma in situ.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Celecoxib; Exemestane
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms ERISAC
  • Most Recent Events

    • 23 Feb 2010 Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 17 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top